Q4 2017: Probi achieves major milestone in expansion of Functional Food business area

Highlights and significant events in the fourth quarter

  • Major agreement signed with global FMCG leader to launch Functional Food product in North America in 2019
  • Important product launches of FerroSorb® and Probi Select™ in North America start to deliver cross-selling synergies in Consumer Healthcare
  • Submission of new health claim application to EFSA for iron uptake product FerroSorb® following positive results in supplementary study
  • Board of Directors and CEO propose that the 2018 Annual General Meeting resolves that no dividends will be paid for the 2017 financial year

Financial overview

MSEK   Full-year 2017   Full-year 2016
Net sales   612.2   443.5
Net sales growth, local currency, %   38.2%   103.2%
Gross margin, %   45.4%   61.0%
EBITDA   157.3   152.6
EBITDA margin, %   25.7%   34.4%
Operating profit (EBIT)   104.1   120.0
Net income   69.1   101.8
Earnings per share before and after dilution, SEK   6.06   10.73
Share price on closing day, SEK   340.00   475.50
Market cap on closing day   3,874.0   5,417.9
See note 5 for definitions of ratios not defined according to IFRS and note 4 for adjustments made to full-year 2016        

Invitation to Teleconference
Date: 25 January 2018
Time: 10:00 a.m.
Phone: +46 8 56 64 26 97
Participants from Probi:
Peter Nählstedt, CEO and Jörn Andreas, CFO

The presentation is available at www.probi.com and www.financialhearings.com

Peter Nählstedt, CEO: Phone: +46 46 286 89 23, E-mail: peter.nahlstedt@probi.com
Jörn Andreas, CFO: Phone: +46 46 286 89 41, E-mail: jorn.andreas@probi.com

About Probi
Probi AB is a Swedish publicly traded bioengineering company. The vision of Probi is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company with four centres of excellence, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2017, Probi had net sales of MSEK 612. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi has about 5,000 shareholders. 

The information in year-end report is such information that Probi AB is obliged to make public pursuant to the Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, at 8:00 a.m. CET on 25 January 2018. When in doubt, the Swedish wording prevails.


About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.


Documents & Links